Prevalence of persistent platelet reactivity despite use of aspirin: A systematic review

2007/01/18 by Marcel M.C. Hovens, Jaapjan D. Snoep, Jeroen Eikenboom +5 · 30 citations
Medicine · #Antiplatelet Therapy and Cardiovascular Diseases #Platelet Disorders and Treatments #Inflammatory mediators and NSAID effects

paper · doi:10.1016/j.ahj.2006.10.040

Cited by

• Multiple anti‐atherosclerotic treatments impair aspirin compliance: effects on aspirin resistance
• Aspirin “resistance” and risk of cardiovascular morbidity: systematic review and meta-analysis
• Antiplatelet resistance in stroke
• Association of Laboratory-Defined Aspirin Resistance With a Higher Risk of Recurrent Cardiovascular Events
• Residual platelet reactivity on aspirin therapy and recurrent cardiovascular events — A meta-analysis
• Assessment of aspirin resistance varies on a temporal basis in patients with ischaemic heart disease. [europepmc]
• 'Aspirin resistance' or treatment non-compliance: which is to blame for cardiovascular complications? [europepmc]
• Aspirin Resistance in healthy drug-naive men versus women (from the Heredity and Phenotype Intervention Heart Study). [europepmc]
• Aspirin for primary prevention of cardiovascular disease in diabetes mellitus. [europepmc]
• Antiplatelet resistance in stroke. [europepmc]
• Effect of aspirin dose on mortality and cardiovascular events in people with diabetes: a meta-analysis. [europepmc]
• Antiplatelet resistance and thromboembolic complications in neurointerventional procedures. [europepmc]
• Aspirin resistance: current status and role of tailored therapy. [europepmc]
• The combination of EPA+DHA and low-dose aspirin ingestion reduces platelet function acutely whereas each alone may not in healthy humans. [europepmc]
• Purine pathway implicated in mechanism of resistance to aspirin therapy: pharmacometabolomics-informed pharmacogenomics. [europepmc]
• Greater collagen-induced platelet aggregation following cyclooxygenase 1 inhibition predicts incident acute coronary syndromes. [europepmc]
• Predicting Bleeding Risk by Platelet Function Testing in Patients Undergoing Heart Surgery. [europepmc]
• Use of Aspirin and P2Y12 Response Assays in Detecting Reversal of Platelet Inhibition With Platelet Transfusion in Patients With Traumatic Brain Injury on Antiplatelet Therapy. [europepmc]
• Utility of the Aspirin and P2Y12 Response Assays to Determine the Effect of Antiplatelet Agents on Platelet Reactivity in Traumatic Brain Injury. [europepmc]
• Aspirin as a COX inhibitor and anti-inflammatory drug in human skeletal muscle. [europepmc]
• Platelet Aggregometry Testing: Molecular Mechanisms, Techniques and Clinical Implications. [europepmc]
• vWF/ADAMTS13 is associated with on-aspirin residual platelet reactivity and clinical outcome in patients with stable coronary artery disease. [europepmc]
• Impaired aspirin-mediated platelet function inhibition in resuscitated patients with acute myocardial infarction treated with therapeutic hypothermia: a prospective, observational, non-randomized single-centre study. [europepmc]
• Inhibition of high shear arterial thrombosis by charged nanoparticles. [europepmc]
• Impact of genetic polymorphisms on platelet function and response to anti platelet drugs. [europepmc]
• Clopidogrel Resistance in Lower Extremity Arterial Endovascular Interventions. [europepmc]
• Association among PlA1/A2 gene polymorphism, laboratory aspirin resistance and clinical outcomes in patients with coronary artery disease: An updated meta-analysis. [europepmc]
• Influence of low-dose aspirin, resistance exercise, and sex on human skeletal muscle PGE 2 /COX pathway activity. [europepmc]
• Aspirin Resistance in Vascular Disease: A Review Highlighting the Critical Need for Improved Point-of-Care Testing and Personalized Therapy. [europepmc]
• Interindividual variability in platelet reactivity among individuals with or without antiplatelet therapy: results from a large tertiary care hospital. [europepmc]